Issue

Vol. 66 No. 6: Issue 6

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone

https://doi.org/10.14715/cmb/2020.66.6.5
Yuanyuan Sun
Department of General Medicine, Hefei Hospital Affiliated to Anhui Medical University/The No.2 People's Hospital of Hefei，Hefei，Anhui230011，China.
Qigui Yu
Department of General Medicine, Hefei Hospital Affiliated to Anhui Medical University/The No.2 People's Hospital of Hefei，Hefei，Anhui230011，China.
Jun Xie
Department of General Medicine, Hefei Hospital Affiliated to Anhui Medical University/The No.2 People's Hospital of Hefei，Hefei，Anhui230011，China

Corresponding Author(s) : Yuanyuan Sun

lqd840@163.com

Cellular and Molecular Biology, Vol. 66 No. 6: Issue 6

Abstract

This study was founded for the purpose investigate the differences in effects of combined medication of pioglitazone and melbine and single-use of pioglitazone on the levels of hba1c, blood fat and insulin sensitivity of elder patients with type II diabetes mellitus (T2DM), to provide clinical reference and guidance for the treatment of T2DM in elder patients. For this purpose, we selected a total of 120 elder patients with T2DM who visited the clinic or were admitted to this hospital between July 2016 and July 2017 and divided them into the observation group and the control group (n=60 for each group). For the control group, they only took pioglitazone for treatment, while those in the observation additionally took melbine for treatment. Then, we observed the levels of FPG, 2hPG, HbA1c, blood fat, FINS, 2hINS and HOMA-IR. Results showed that after treatment, significant decreases were seen in levels of FPG, 2hPG and HbA1c in patients of two groups compared to the levels before treatment, and the levels in the observation group decreased more evidently than those in the control group (p<0.05); besides, the levels of total glyceride, total cholesterol and LDL-C were all significantly lower than those before treatment, with an elevated HDL-C, and those levels of TG, TC and LDL-C in the observation group were significantly lower than those in the control group; the level of HDL-C was higher than the control group (p<0.05). Similar decreases were identified in the levels of FINS, 2hFINS and HOMA-IR after treatment (p<0.05), and the levels in the observation group were also significantly lower than those in the control group (p<0.05). In the observation group, the incidence rate of adverse reactions was 10% (6/60), while in the control group was 8.33% (5/60), but the difference between the two groups showed no statistical significance (p>0.05). It is concluded that combined medication of pioglitazone and melbine can effectively reduce the levels of plasma glucose, blood fat and the HOMA-IR, with an elevated sensitivity to insulin, but no severe adverse reactions, manifesting a promising safety in long-term administration. It is worthy of being promoted in clinical practice.

Keywords

Pioglitazone Melbine T2DM HbA1c Blood fat Insulin.
Sun, Y., Yu, Q., & Xie, J. (2020). Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone. Cellular and Molecular Biology, 66(6), 21–28. https://doi.org/10.14715/cmb/2020.66.6.5
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. American Diabetes Association. Standards of medical care in diabetes–2013. Diabetes Care2013; 36: S11–S66.
  2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient"centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–1379.
  3. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W, Canagliflozin DIA. Dose"ranging effects of canagliflozin, a sodium"glucose cotransporter 2 inhibitor, as add"on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232–1238.
  4. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance Diabetes Res. Clin. Pract., 76 (2007),
  5. pp. 24-29
  6. Bełtowski J. Apelin and visfatin: unique. Medical Science Monitor. 2006; 12(6): RA112-119.
  7. Yki-Järvinen H. Thiazolidinediones New Engl J Med 2004; 351: 1106-1118
  8. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update Ann Intern Med 2002; 137: 25-33.
  9. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N. Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 2001; 108(8): 1167-1174.
  10. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabol 56 (2007), pp. 451-458
  11. Hsieh CH, He CT, Lee CH, Wu LY, Hung YJ. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabol 2007; 56: 1087-1092.
  12. Riera"Guardia N, Rothenbacher D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab (2008); 10: 367-375
  13. Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, Nam M, Chung CH, Lee KW, Nam CM, Lee HC. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol 2007; 66: 282-289
  14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetol 1985; 28: 412-419
  15. Samara A, Pfister M, Marie B, Visvikis"Siest S. Visfatin, low-grade inflammation and BMI Clin Endocrinol 2008; 69: 568-574
  16. Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, Shang W, Li F, Ma Q, Yang Y, Chen M. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008; 79: 412-418.
  17. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance Clin Endocrinol (Oxf.) 2007; 67: 796-800.
  18. Wang P, van Greevenbroek MM, Bouwman FG, Brouwers MC, van der Kallen CJ, Smit E, Keijer J, Mariman EC. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007; 454: 971-976
  19. Ingelsson E, Larson MG, Fox CS, Yin X, Wang TJ, Lipinska I, Pou KM, Hoffmann U, Benjamin EJ, Keaney JF, Vasan RS. Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 2007; 30(5): 1278-1280.
  20. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005; 11(8):344-347.
  21. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats Biochem Biophys Res Commun 2005; 336: 747-753.
  22. Ando H, Yanagihara H, Hayashi Y, Obi Y, Tsuruoka S, Takamura T, Kaneko S, Fujimura A. Rhythmic messenger ribonucleic acid expression of clock genes and adipocytokines in mouse visceral adipose tissue. Endocrinol 2005; 146(12): 5631-5636.
  23. Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V, Gogg S, Jansson PA, Laakso M, Smith U. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006; 91(3):1181-1184.
  24. De Jager J, Kooy A, Lehert PH, Bets D, Wulffele MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD. Effects of short"term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo"controlled trial. J Intern Med 2005; 257(1):100-9.
  25. Kalan MJ, Fogle RH, Baker MB, Allen RB, Sokol RJ, Stanczyk FZ. The effect of metformin on serum visfatin in relation to polycystic ovarian syndrome, obesity and insulin resistance Fertil Steril 2007; 88: S78.
  26. Ibáñez L, López"Bermejo A, Dí­az M, Enrí­quez G, Valls C, De Zegher F. Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clin Endocrinol 2008; 68: 317-320
  27. Pfützner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, Köhler C, Hohberg C, Forst T. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk: results from the PIOSTAT study Horm Metab Res 2007; 39: 764-768
  28. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 2007; 292: 1655-1663
  29. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease Curr Opin Lipidol 2003; 14: 561-566.
  30. P Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf.) 2006; 65: 722-728.
  31. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus Exp. Clin Endocrinol Diabetes 2008; 116; 289-292.
  32. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003; 52(3): 667-674.
  33. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53(8): 2169-2176.
  34. Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, Alevizos M. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25(3): 333-40.
  35. Ikeda Y, Osaki F, Maruyama H, Inada S, Shinahara M, Inoue K, Takata H, Suehiro T, Hashimoto K. The effect of pioglitazone on circulating adiponectin is highly predictable based on its basal level. Diabetes Res Clin Pract 2008; 80: 12-13.
  36. Eftekharinasab N, Zarei D, Paidar S, Moghadam MJ, Kahrizi D, Khanahmadi M, Chenari P. Identification of wild medicinal plant in Dalahoo mountain and their used indigenous knowledge (Kermanshah, Iran). Ann Biol Res 2012; 3(7): 3234-9.
  37. Kazemi N, Kahrizi D, Mansouri M, Karim H, Vaziri S, Zargooshi J, Khanahmadi M, Shokrinia M, Mohammadi N. Induction of linalool as a pharmaceutical and medicinal metabolite via cell suspension culture of cumin (Cuminum cyminum L.). Cell Mol Biol 2016; 62(6): 65-68.
  38. Ghaheri M, Miraghaee S, Babaei A, Mohammadi B, Kahrizi D, Haghighi ZS, Bahrami G. Effect of Stevia rebaudiana Bertoni extract on sexual dysfunction in Streptozotocin-induced diabetic male rats. Cell Mol Biol 2018; 64: 6-10.
  39. Zebarjadi A, Kazem S, Kahrizi D. Cell dedifferentiation and multiplication of Burdock (Arctium Lappa) as a medicinal plant. Cell Mol Biol 2018; 64(7): 92-96.
  40. Keshvari T, Najaphy A, Kahrizi D, Zebarjadi A. Callus induction and somatic embryogenesis in Stevia Rebaudiana Bertoni as a medicinal plant. Cell Mol Biol 2018; 64(2): 46-49.
  41. Bordbar M, Darvishzadeh R, Pazhouhandeh M, Kahrizi D. An overview of genome editing methods based on endonucleases. Modern Genetics J 2020; 15(2): 75-92.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 880 Download : 477